One Company's Search for an Effective Antiviral Contrasts Another's Scramble for the Easy Money The Perils & Pains of Integrity Early on a rainy Monday morning, Merck scientists Emilio Emini and John Ryan assembled overheads and flip charts before a…
Study After Study, Antiretroviral Analyses Confound More Than They Clarify Lamenting the Naked Emperor First there was Concorde, the now notorious Anglo-French study which last summer sent shock waves across the Atlantic as it cast doubt on the wisdom of…
TAG and other partner organizations issued this letter about their serious and unresolved concerns about the proposed clinical trial comparing stavudine at 20 mg to tenofovir.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
The exorbitant price of AIDS medicines, especially antiretrovirals, has been one of the main barriers to people with HIV accessing them, especially in developing countries. As activist organisations we have been at the forefront of many of the struggles to make medicines affordable.
A cure for HIV will be an essential part of ending the pandemic. In the past three years, increasing scientific momentum has been evident in research aimed at curing HIV infection (Lehrman 2005; Richman 2009; Trono 2010; Palmer 2011). The…
By Mark Harrington A cure for HIV is possible: one man, the so-called Berlin patient, has already been cured of chronic HIV infection with an immune system transplant with cells genetically resistant to HIV. After four years, the man remains…
By Richard Jefferys The research effort to discover a cure for HIV infection continues to gain momentum, with several important developments having occurred since the last issue of TAGline. In July, the National Institute of Allergy and Infectious Diseases (NIAID)…
Success rate for new ARVs entering phases II–III surpassed 32% from 2003–2011 U.S. ADAP Prescribing Practices Closely Match Recent ARV Guidelines by Polly Clayden and Mark Harrington As we were putting together the 2011 Pipeline Report this summer, we decided…